

## **Ninth Annual Scientific Retreat**

February 13–15, 2017 Washington, DC

## **AGENDA**

The Ritz-Carlton Hotel | Washington DC, 1150 22<sup>nd</sup> Street, NW

Monday, February 13 <sup>th</sup>		
7:30 am-5:00 pm	Grant Review Committee Meeting (by invitation)Plaza Ballroom	
10:30-12:30 pm	MAC internal meeting (by invitation)Roosevelt	
12:00-6:00 pm	Registration open Salon Ballroom Foyer	
1:00-5:30 pm	Melanoma Advocates & Foundations Forum (by invitation)	
6:00-7:30 pm	Opening Reception Salon I & II Foyer	
Tuesday, February 14 <sup>th</sup>		
raesaay, residary	<u>-</u>	
6:30 am-6:00 pm	Registration openOutside Salon Ballrooms	
7:00-8:15 am	General BreakfastSalon III	
7:00-8:15 am	Young Investigators Breakfast (by invitation only)Plaza Ballroom	
8:30-8:45 am	Opening RemarksSalon I & II  Michael Kaplan, MRA President and CEO  Louise Perkins, MRA Chief Science Officer  Introduction by Ross King & President Carter welcome video	
8:45-9:15 am	<b>Lecture:</b> Jedd Wolchok, Memorial Sloan Kettering Cancer Center: Immunotherapy for melanoma – where do we go from here?	
9:15-11:25 am	Session 1: Biological Basis of Therapeutic Resistance Chair: Roger Lo	
9:15-9:40	Neal Rosen, Memorial Sloan Kettering Cancer Center: Development of an equipotent inhibitor of mutant RAF monomers and dimers	
9:40-10:00	Piyush Gupta, Whitehead Institute: Mechanisms of tolerance to Ras pathway inhibition in BRAF-mutant melanomas	
10:00-10:20	Brent Hanks, Duke University: Inhibiting the TGF-ß signaling axis in the melanoma microenvironment	
10:20-10:40	Break	



## **Ninth Annual Scientific Retreat**

February 13–15, 2017 Washington, DC

10:40-11:00	Bin Zhang, Northwestern University: Overcoming resistance to agonist immunotherapeutics
11:00-11:25	Roger Lo, UCLA: Resistance to MAPK and PD-1 targeted therapies
11:25-11:55 am	<b>Lecture:</b> Richard Scolyer, University of Sydney: Using whole genome sequencing to reveal differences between acral, mucosal and cutaneous melanomas: Data from the Australian melanoma genome project
12:00-1:15 pm	Lunch and Fireside Chat: Genes: A Conversation on Cancer Causation and CuresSalon III  Moderator: Michael Milken, Chairman, Milken Institute and MRA Board Member  Siddhartha Mukherjee, Columbia University  Antoni Ribas, UCLA  Steven Rosenberg, U.S. National Cancer Institute
1:30-2:20 pm	Session 2: Germline Influences on Melanoma Salon I & II
1:30-1:55	Hensin Tsao, Massachusetts General Hospital: Mutational landscape of hereditary melanoma
1:55-2:20	Alan Spatz, Lady Davis Institute: The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene
2:20-4:45 pm	Session 3: Models, Markers and New Targets Salon I & I Chair: Meenhard Herlyn
2:20-2:40	Scott Woodman, MD Anderson Cancer Center: Unraveling the functional effects of hallmark genetic aberrations in uveal melanoma
2:40-3:00	Yuhang Zhang, University of Cincinnati: A tale of two stories: Targeting cancer-associated fibroblasts in the melanoma microenvironment
3:00-3:20	Break
3:20-3:40	Alexander Boiko, University of California, Irvine: Activation of innate immunity and targeting of tumor initiating cells effectively suppresses melanoma metastasis
3:40-4:00	Christin Burd, Ohio State University: Ultraviolet radiation accelerates NRAS mutant melanoma genesis: A cooperative effect blocked by sunscreen
4:00-4:20	Tal Burstyn-Cohen, Hebrew University of Jerusalem: TAM receptors in melanoma: Mechanisms and therapeutic efficacy of novel inhibitors
4:20-4:45	Meenhard Herlyn, Wistar Institute: Targeting developmental pathways in melanoma
4:45 pm	Closing Remarks Day 1: Louise Perkins, MRA Chief Science Officer
5:30-6:30 pm	MRA Board Meeting (invitation only)
6:30-9:00 pm	Reception and Dinner

<sup>\*6:15-7:00</sup> pm: Transportation provided to Teddy & Bully Bar; Shuttles will depart from the circular drive outside the hotel lobby. Upon exiting the hotel, bear to your right and shuttles will be stationed in the breezeway between the hotel and art gallery on the property.



## **Ninth Annual Scientific Retreat**

February 13–15, 2017 Washington, DC

Wednesday, February 15 <sup>th</sup>		
6:30-10:00 am	Registration open	
7:00-8:30 am	General BreakfastSalon III	
7:00-8:30 am	Industry Roundtable Breakfast (by invitation only)Plaza Ballroom	
8:40-8:45 am	Opening Remarks Day 2: Kristen Mueller, MRA Scientific Program DirectorSalon I & II	
8:45-11:40 am	Session 4: Overcoming Difficult to Treat Disease Chair: Sheri Holmen	
8:45-9:10	Tanja de Gruijl, VUMC: Harnessing the sentinel lymph node to limit metastatic melanoma	
9:10-9:30	James Moon, University of Michigan: Vaccine nanodiscs for personalized cancer immunotherapy	
9:30-9:50	Xu Chen, UCSF: RasGRP3 mediates MAPK pathway activation in GNAQ mutant uveal melanoma	
9:50-10:15	Andrew Aplin, Thomas Jefferson University: Targeted inhibitors in cutaneous and uveal melanoma: Combinations, reporters and schedules	
10:15-10:35	Break	
10:35-10:55	Jessie Villanueva, Wistar Institute: A promising BETi/MEKi combination strategy for NRAS mutant melanomas	
10:55-11:15	Ana Anderson, Brigham and Women's Hospital: Harnessing Tim-3 pathway blockade for melanoma immunotherapy	
11:15-11:40	Sheri Holmen, University of Utah: Identification and characterization of drivers of melanoma brain metastasis	
11:40-12:20 pm	Panel Discussion: News from the Field: What's going well and what remains to be done? Reinhard Dummer, University Hospital Zurich Keith Flaherty, Massachusetts General Hospital Howard Kaufman, Rutgers University Grant McArthur, Peter MacCallum Cancer Centre Susan Swetter, Stanford University Jennifer Wargo, MD Anderson Cancer Center Suzanne Topalian, Johns Hopkins University (Chair)	
12:20-12:30 pm	Closing Remarks: Elliott Sigal, MRA Board Member	

12:30-1:30 pm Lunch available and departures......Salon III